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Novartis Oncology was described according to the method of Kaplan and Meier and comparisons were made using the log rank test. Results: Fourteen of 47 patients (30%) experienced recurrent or progressive medulloblastoma. The median age at diagnosis was 9 years (range 5.8 to 15.9), and 71% (n=10) were male. Most patients had localized disease (M0, 78.6%), classic histology (78.6%) and gross total resection (92.9%) at initial diagnosis. The median time from diagnosis to recurrence was 18.0 months (range 3.6 -62.6), and site of recurrence was metastatic in 86% (n=12). The median survival after relapse was 6.8 months (range 0.7 -77.9); 3-year survival after relapse was 19%. There were trend associations between longer survival and having received additional chemotherapy (median survival 6.8 vs. 1.3 months, p = 0.06) and radiation therapy (15.4 vs. 4.4 months, p=0.13), but not research therapy (2.8 vs. 10.3 months, p =0.69.) Conclusions:
Recurrence of medulloblastoma is much more likely to be metastatic than reported in previous eras. Within the limits of our small sample, our data suggest a potential survival benefit from re-treatment with cytotoxic chemotherapy and radiation even in heavily pre-treated patients. This report serves as a baseline against which to evaluate novel therapy combinations.
